INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 178 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $6,426,663 | +123.7% | 101,495 | +84.9% | 0.23% | +48.1% |
| Q4 2021 | $2,873,000 | +212.6% | 54,885 | +122.7% | 0.16% | +243.5% |
| Q3 2021 | $919,000 | -66.0% | 24,642 | -62.8% | 0.05% | -56.2% |
| Q2 2021 | $2,704,000 | -38.7% | 66,232 | -49.1% | 0.10% | -26.1% |
| Q1 2021 | $4,412,000 | -29.3% | 130,032 | -33.7% | 0.14% | -55.2% |
| Q4 2020 | $6,237,000 | +116.0% | 196,126 | +74.3% | 0.32% | +77.1% |
| Q2 2020 | $2,888,000 | +456.5% | 112,500 | +181.2% | 0.18% | +397.2% |
| Q2 2019 | $519,000 | -59.0% | 40,000 | -61.5% | 0.04% | -49.3% |
| Q1 2019 | $1,267,000 | -79.7% | 104,000 | -75.9% | 0.07% | -78.4% |
| Q4 2017 | $6,253,000 | +42.3% | 431,874 | +55.1% | 0.33% | +48.4% |
| Q3 2017 | $4,393,000 | +320.0% | 278,400 | +230.6% | 0.22% | +287.7% |
| Q2 2017 | $1,046,000 | +37.3% | 84,200 | +68.4% | 0.06% | +29.5% |
| Q3 2016 | $762,000 | – | 50,000 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |